Future treatment approaches to multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• The modern treatment era for multiple sclerosis (MS) began in 1993 with the first disease-modifying agent.
• Currently, 10 therapies are approved for MS, effectively reducing relapses and slowing disability progression.
• Despite existing treatments, some patients experience continued disease activity and disability due to partial effectiveness.

Purpose of the Study:

• To review the evolution of multiple sclerosis (MS) treatments.
• To discuss emerging therapies and their novel mechanisms of action.
• To explore future directions in MS management, including combination therapies and neuroprotection.

Main Methods:

• Review of scientific literature and clinical trial data.
• Discussion of approved and emerging MS therapies.
• Exploration of novel therapeutic targets and strategies.

Main Results:

• Multiple sclerosis (MS) treatment landscape has expanded significantly since 1993.
• Approved therapies reduce relapses and MRI activity but have limitations in effectiveness for some patients.
• Emerging therapies offer novel mechanisms and potential for greater efficacy.

Conclusions:

• The future of multiple sclerosis (MS) treatment is promising with the exploration of new molecules and targets.
• Emerging therapies like alemtuzumab, rituximab, and stem cell transplantation show potential for enhanced efficacy.
• Further research into combination therapies, neuroprotection, and repair is crucial for advancing MS care.